Pyrimido compounds having antiproliferative activity

Details Pyrimido compounds having antiproliferative activity Pyrimido compounds having antiproliferative activity

2006-10-31

2006-10-31

McKenzie, Thomas C. (Department: 1624)

Organic compounds -- part of the class 532-570 series

Organic compounds

Four or more ring nitrogens in the bicyclo ring system

C514S262100

Reexamination Certificate

active

07129351

ABSTRACT:
Disclosed are novel pyrimido compounds that are inhibitors of Src family of tyrosine kinases. These compounds and their pharmaceutically acceptable salts are anti-proliferative agents useful in the treatment or control of solid tumors, in particular breast, colon, hepatic and pancreatic tumors. Also disclosed are pharmaceutical compositions containing these compounds and methods of treating cancer.

REFERENCES:
patent: 2949466 (1960-08-01), Hoefle et al.
patent: 3939084 (1976-02-01), Sullivan
patent: 4425346 (1984-01-01), Horlington
patent: 4886807 (1989-12-01), Kitamura et al.
patent: 6150373 (2000-11-01), Harris et al.
patent: 6451804 (2002-09-01), Dunn et al.
patent: 2004/0019210 (2004-01-01), Connolly et al.
patent: 2004/0097485 (2004-05-01), Burkitt et al.
patent: WO 98/24432 (1998-06-01), None
patent: WO 99/61444 (1999-12-01), None
patent: WO 00 24744 (2000-05-01), None
patent: WO 01/29041 (2001-04-01), None
patent: WO 01/29042 (2001-04-01), None
patent: WO 01/64679 (2001-09-01), None
patent: WO 02/18380 (2002-03-01), None
patent: WO 03/062236 (2003-07-01), None
Draetta, G. and Pagano, M. in “Annual Reports in Medicinal Chemistry, vol. 31”, 1996, Academic Press, San Diego, p. 241-246.
Noble, M.E.M. et al, Science, vol. 303, 2004, pp. 1800-1805.
Anderson, M.R. et al, Expert Opin. Investig. Drugs, 2003, 12(4) 577-592.
Laird, A.D. et al, Expert Opin. Investig. Drugs, 2003, 12(1), 51-64.
Traxler, Peter, Expert Opin. Ther. Targets, 2003, 7(2) 215-234.
Sawyer, Tomi et al, Expert. Opin. Investig. Drugs, 2001, 10(7), 1327-1344.
Sawyer, Tomi et al, Expert. Opin. Investig. Drugs, 2004, 13(1), 1-19.
Anderson, M.R. et al, Expert Opin. Investig. Drugs, 2003, 12(4) 577-592.
Laird, A.D. et al, Expert opin. Investig. Drugs, 2003, 12(1), 51-64.
Traxler, Peter, Expert Opin. Ther. Targets, 2003, 7(2) 215-234.
Hennequin L. F. et al., J. Med. Chem. 2002, vol. 45(6) pp. 1300-1312.
Klohs W. E. et al., Current Opinion in Biotechnology, 1999 vol. 10, pp. 544-549.
D. H. Boschelli & F. Boschelli, Drugs of the Future, 2000 25(7) pp. 717-736.
Ansel, H. et al.,Pharmaceutical Dosage Forms&Drug Delivery Systems6thEd. 1995, p. 196.
J. Alexander, et al.,J. Med. Chem. 1988, vol. 31, pp. 318-322.
Masquelin et al.,Helvetica Chimica Acta,vol. 81 (1998) pp. 646-659.
Devi, et al.,Indian Journal of Heterocyclic Chemistry,vol. 7, Jan.-Mar. 1998, pp. 193-196.
Tominaga et al.,Chemical&Pharmaceutical Bulletin,vol. 32, No. 1, Jan. 1984, pp. 122-129.
Tominaga et al.,Heterocycles,vol. 12, No. 4. 1979, pp. 503-504.
Marsh et al.,Chemical Communications,1996, pp. 1527-1528.
Z. Chem. 20Jg (1980) Heft. 11, pp. 412-413.
Cappuccino et al.,Cancer Research,vol. 24, Aug. 1964, pp. 1243-1248.
Chatterjee et al.,J. Sci. Industr. Res.,vol. 17B, Feb. 1958, pp. 63-70.
Chatterjee et al.,J. Sci. Industr. Res.,vol. 18B, Jul. 1959, pp. 272-278.
Graboyes et al.,Pteridines X.,vol. 11 Jan. 6, 1968, pp. 568-573.
Grohe et al.,Liebigs Ann. Chem.,1974, pp. 2066-2073.
Gulevskaya et al.,Chemistry of Heterocyclic Compounds,vol. 30, No. 9, 1994, pp. 1083-1091.
Hirota et al.,J. Chem. Soc. Perkin Trans. 1,1990, pp. 123-128.
Srivastava, et al.,Combinatorial Chemistry&High Throughout Screening,1999, 2, pp. 33-37.
Taylor et al.,Pyrimido [4,5-D]Pyrimidines,vol. 82, pp. 5711-5718.
Wamhoff et al.,Heterocycles,vol. 35, No. 2, 1993, pp. 1055-1066.
M. Hirota et al., “A Facile Synthesis of 7-Substituted Pyrimido[4,5-d]-Pyrimidine-2,4-diones”, Synthesis, pp. 589-590 (1984).
Talpaz, M. et al., 2005 ASCO Annual Meeting: Abstract No. 6519, Leukemia, Lymphoma, Myeloma, and Transplantation (Adult), A Phase I Study of BMS-354825 in Patients with Imatinib-Resistant and Intolerant Chronic Phase Chronic Myeloid Leukemia (CML): Results from CA 180002.

Affiliated with

Also associated with

Rating

Pyrimido compounds having antiproliferative activity does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Pyrimido compounds having antiproliferative activity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrimido compounds having antiproliferative activity will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3637498